TP53 is commonly altered in human cancer, and Tp53 reactivation suppresses tumours in vivo in mice 1,2 (TP53 and Tp53 are also known as p53). This strategy has proven difficult to implement therapeutically, and here we examine an alternative strategy by manipulating the p53 family members, Tp63 and Tp73 (also known as p63 and p73, respectively). The acidic transactivation-domain-bearing (TA) isoforms of p63 and p73 structurally and functionally resemble p53, whereas the DN isoforms (lacking the acidic transactivation domain) of p63 and p73 are frequently overexpressed in cancer and act primarily in a dominant-negative fashion against p53, TAp63 and TAp73 to inhibit their tumour-suppressive functions 3-8 . The p53 family interacts extensively in cellular processes that promote tumour suppression, such as apoptosis and autophagy 9-14 , thus a clear understanding of this interplay in cancer is needed to treat tumours with alterations in the p53 pathway. Here we show that deletion of the DN isoforms of p63 or p73 leads to metabolic reprogramming and regression of p53-deficient tumours through upregulation of IAPP, the gene that encodes amylin, a 37-amino-acid peptide co-secreted with insulin by the b cells of the pancreas. We found that IAPP is causally involved in this tumour regression and that amylin functions through the calcitonin receptor (CalcR) and receptor activity modifying protein 3 (RAMP3) to inhibit glycolysis and induce reactive oxygen species and apoptosis. Pramlintide, a synthetic analogue of amylin that is currently used to treat type 1 and type 2 diabetes, caused rapid tumour regression in p53-deficient thymic lymphomas, representing a novel strategy to target p53-deficient cancers.
TP53 is commonly altered in human cancer, and Tp53 reactivation suppresses tumours in vivo in mice 1, 2 (TP53 and Tp53 are also known as p53). This strategy has proven difficult to implement therapeutically, and here we examine an alternative strategy by manipulating the p53 family members, Tp63 and Tp73 (also known as p63 and p73, respectively). The acidic transactivation-domain-bearing (TA) isoforms of p63 and p73 structurally and functionally resemble p53, whereas the DN isoforms (lacking the acidic transactivation domain) of p63 and p73 are frequently overexpressed in cancer and act primarily in a dominant-negative fashion against p53, TAp63 and TAp73 to inhibit their tumour-suppressive functions [3] [4] [5] [6] [7] [8] . The p53 family interacts extensively in cellular processes that promote tumour suppression, such as apoptosis and autophagy [9] [10] [11] [12] [13] [14] , thus a clear understanding of this interplay in cancer is needed to treat tumours with alterations in the p53 pathway. Here we show that deletion of the DN isoforms of p63 or p73 leads to metabolic reprogramming and regression of p53-deficient tumours through upregulation of IAPP, the gene that encodes amylin, a 37-amino-acid peptide co-secreted with insulin by the b cells of the pancreas. We found that IAPP is causally involved in this tumour regression and that amylin functions through the calcitonin receptor (CalcR) and receptor activity modifying protein 3 (RAMP3) to inhibit glycolysis and induce reactive oxygen species and apoptosis. Pramlintide, a synthetic analogue of amylin that is currently used to treat type 1 and type 2 diabetes, caused rapid tumour regression in p53-deficient thymic lymphomas, representing a novel strategy to target p53-deficient cancers.
Using DNp63 (ref. 15 ) and DNp73 conditional knockout mice (Extended Data Fig. 1a , b), we generated DNp63 1/2 and DNp73 2/2 mice (Extended Data Fig. 1c-f ). To ask whether the DN isoforms of p63 and p73 act as oncogenes in vivo by interacting with p53, DNp63 1/2 ;p53 2/2 and DNp73 2/2 ;p53 2/2 mice were aged for the development of thymic lymphomas, which form in nearly all p53 2/2 mice 16 . We found a remarkable diminution in the number and size of thymic lymphomas in DNp63 1/2 ;p53 2/2 and DNp73 2/2 ;p53 2/2 mice, leading to an extended lifespan (Extended Data Fig. 2a -c) and suggesting that the DN isoforms of p63 and p73 restrain a tumour suppressive program that can compensate for p53 function.
We found that TAp63 and TAp73 were upregulated in thymic lymphomas from DNp63 1/2 ;p53 2/2 and DNp73 2/2 ;p53 2/2 mice (Extended Data Fig. 2d , e) along with an upregulation of apoptosis (Extended Data Fig. 2f -j) and senescence (Extended Data Fig. 2k-o) . We also examined thymocytes from 4-week-old mice after treatment with 10 Gy gamma irradiation, a dose that is known to elicit p53-dependent apoptosis 9, 17 .
Indeed, TAp63 and TAp73 are higher in DNp63 1/2 ;p53 2/2 and DNp73 2/2 ; p53 2/2 thymocytes, which was further exacerbated after gamma irradiation (Extended Data Fig. 3a-c) with an increase in apoptosis (Extended Data Fig. 3d -h) and senescence (Extended Data Fig. 3i-m) .
To determine whether TAp63 or TAp73 compensate for p53 function in tumours in vivo, we acutely removed DNp63 or DNp73 by intratumoral infection with adenovirus-Cre-mCherry (Extended Data Fig. 4a-d and Fig. 1a -f) in DNp63 fl/fl ;p53 2/2 and DNp73 fl/fl ;p53 2/2 at 10 weeks of age. Tumours were 2.3-5.8 mm 3 in size at the time of infection and monitored weekly by magnetic resonance imaging (MRI; Fig. 1a -i). Mice deficient for either DNp63 or DNp73 and p53 showed marked decreases in tumour burden (Fig. 1h, i) . The reduction of DNp63 and DNp73 expression resulted in increased expression of TAp63 and TAp73 (Fig. 1j-m and Extended Data 4d) and increased apoptosis (Extended Data Fig.  4e -h) and senescence (Extended Data Fig. 4i-k) . DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 mice also had an increased lifespan ( Fig. 1n ). We found differences in CD4/CD8-positive cells in young mice (4 weeks) (Extended Data Fig. 4l-p) , indicating that changes in T-cell development may lead to a lower tumour incidence in double-mutant mice. Indeed, we found that p53 2/2 thymic lymphomas are composed primarily of CD4/CD8 double-positive thymocytes while the DNp63 D/D ;p53 2/2 and DNp73 D/D ; p53 2/2 lymphomas contain very few CD4/CD8 double-positive thymocytes (Extended Data Fig. 4q -t). Lastly, we asked whether thymic stromal cells contribute to the apoptosis in the regressing lymphomas. We sorted CD45-positive cells to select for T lymphocytes in p53 2/2 , DNp63 fl/fl ;p53 2/2 and DNp73 fl/fl ;p53 2/2 mice and infected them with adenovirus-Cre (Extended Data Fig. 4u ). DNp63 D/D ;p53 2/2 and DNp73 D/D ; p53 2/2 thymocytes underwent apoptosis independent of the presence of the stromal cells (Extended Data Fig. 4v ). These data indicate that inhibition of the DN isoforms of p63 and p73 serves to upregulate TAp63 and TAp73 to compensate for loss of p53 in tumour suppression.
We found that the DN isoforms of p63 and p73 bind to the promoters of the TA isoforms of p63 and p73, suggesting that the DN isoforms of p63 and p73 can transcriptionally repress TAp63 and TAp73 transcription (Extended Data Fig. 5a -i). We also found that the increase in apoptosis and cellular senescence was dependent on TAp63 and TAp73 (Extended Data Fig. 5j -q).
We performed RNA sequencing of lymphomas after infection with Ad-mCherry (DNp63 fl/fl ;p53 2/2 and DNp73 fl/fl ;p53 2/2 ) and Ad-Cre-mCherry (DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 ) and found that thymic lymphomas from mice deficient for p53 and DNp63 clustered with those from mice deficient for p53 and DNp73 (Extended Data Fig. 6a ). Ingenuity pathway analysis (IPA) ( Fig. 1q ) revealed genes involved in metabolism including TP53-inducible glycolysis and apoptosis regulator (TIGAR) 18 , and glutaminase 2 (GLS2) 19, 20 . While we found that TIGAR and GLS2 were upregulated in either DNp63 D/D ;p53 2/2 or DNp73 D/D ;p53 2/2 thymic lymphomas, we identified a novel gene, islet amyloid polypeptide (IAPP) or amylin, which was upregulated by over fivefold in both double-mutant thymic lymphomas. IAPP limits glucose uptake, resulting in increased intracellular glucose-6-phosphate (G-6-P) 21 levels and decreased glycolysis 21 . We validated IAPP, TIGAR and GLS2 expression in thymic lymphomas derived from DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 mice and found that IAPP is expressed at levels over twofold higher in double-mutant mice ( Fig. 1p and Extended Data Fig. 6b-d ). IAPP and GLS2 expression depend on TAp63 and TAp73 ( Fig. 1q and Extended Data Fig. 6d ). To determine whether TAp63 or TAp73 transcriptionally regulate IAPP, we performed chromatin immunoprecipitation in mouse embryonic fibroblasts (MEFs; Extended Data Fig. 6e -g) and thymocytes ( Fig. 1r, s ). We found that TAp63 and TAp73 bind to sites located in the promoter (site 1), 1,756 nucleotides upstream of the transcriptional start site, and intron 2 (site 2) of IAPP, 706 nucleotides downstream of the transcriptional start site (Extended Data Fig. 6e-g) . Because a greater binding affinity of TAp63 and TAp73 was detected in the promoter region (site 1) of IAPP, we cloned this site into a luciferase reporter gene and also mutated this site (Extended Data Fig. 6h-k ). Only the luciferase reporter gene containing wild-type IAPP promoter site 1 was transactivated by TAp63 and TAp73 whereas the mutant version was not. Taken together, these data indicate that IAPP is a transcriptional target gene of TAp63 and TAp73 ( Fig. 1t ).
Expression of IAPP in p53 2/2 MEFs resulted in low levels of glycolysis comparable to that in DNp63 2/2 ;p53 2/2 and DNp73 2/2 ;p53 2/2 MEFs (Extended Data Fig. 6l -m and Fig. 1u ). Conversely, when we knocked down IAPP in DNp63 2/2 ;p53 2/2 and DNp73 2/2 ;p53 2/2 MEFs, the levels of glycolysis were similar to that of p53 2/2 MEFs (Fig. 1u ) indicating that IAPP inhibits glycolysis. In vivo, we detected massive tumour regression in DNp63 fl/fl ;p53 2/2 or DNp73 fl/fl ;p53 2/2 thymic lymphomas treated with IAPP (Extended Data Fig. 7a and Fig. 2a , b, h, i, o, p), P , 0.05. Conversely, in DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 thymic lymphomas treated with Ad-shIAPP-mCherry the tumours continued to grow comparable to that of p53 2/2 thymic lymphomas ( Fig. 2a -k, o-r), P . 0.05 at 13 weeks. Additionally, p53 2/2 mice treated with Ad-IAPP had an extended tumour-free survival period compared to p53 2/2 mice or DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 mice treated intratumorally with Ad-shIAPP-mCherry (Extended Data Fig. 7a, b ), indicating that IAPP is a tumour suppressor gene and is causally involved in the in vivo effects seen upon inactivation of DNp63 or DNp73. Given that pramlintide, a synthetic analogue of amylin, is used to treat type I and type II diabetes 22 , we treated thymic lymphomas in DNp63 fl/fl ;p53 2/2 and DNp73 fl/fl ;p53 2/2 mice. Indeed, three-weekly intratumoral injections resulted in rapid tumour regression ( Fig. 2e , l, s), P , 0.005 at 13 weeks. This effect was exacerbated by systemic intravenous treatment with 
ΔNp73 TAp63 TAp73 LETTER RESEARCH pramlintide ( Fig. 2f , m, t and Extended Data Fig. 7c -q), P , 0.005, similar to that seen in tumours treated with a known inhibitor of glycolysis, 2-deoxy-D-glucose (2DG; Fig. 2g , n, u). These data provide preclinical in vivo evidence that pramlintide can be used to effectively treat p53-deficient tumours. Using in vivo dynamic magnetic resonance spectroscopy to measure the conversion of hyperpolarized [1-13 C]pyruvate to lactate as a proxy of glycolysis within the tumours, we found a marked reduction in glycolysis in DNp63/p53 and DNp73/p53 double-deficient mice and after introducing IAPP into p53 2/2 thymic lymphomas similar to tumours treated with 2DG ( Fig. 2v ). DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 thymic lymphomas infected with a short hairpin RNA for IAPP exhibited levels of glycolysis similar to those found in p53 2/2 thymic lymphomas ( Fig. 2v ). Pramlintide also inhibits glycolysis in tumours ( Fig. 2v ). IAPP has been shown to induce reactive oxygen species (ROS) and activate apoptosis 23, 24 . We found a marked increase in the levels of ROS and apoptosis in thymic lymphomas expressing IAPP or treated with pramlintide or 2DG, whereas neither ROS nor apoptosis occurred upon inactivation of IAPP in thymic lymphomas from DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 mice ( Fig. 2w ), indicating that upregulation of IAPP inhibits glycolysis similarly to 2DG and leads to oxidative stress that triggers apoptosis. While high levels of ROS are not commonly triggered by inhibition of glycolysis, nutrient deprivation or excess can result in the accumulation of ROS. Additionally, cancer cells tightly regulate ROS by acquiring additional mutations and compensatory mechanisms often ensue and may be at play in the thymic lymphoma cells that acutely downregulate glycolysis by IAPP 25 .
To extend our findings to human cancer where p53 is altered in the majority of cases, we analysed human cancer cell lines containing p53 deletions or mutations. We used short interfering RNA (siRNA) to knockdown DNp63 or DNp73 in cells derived from a lung adenocarcinoma (H1299) ( Fig. 3a ). Downregulation of DNp63 or DNp73 resulted in upregulation of TAp63, TAp73 and IAPP ( Fig. 3a) and an increase in apoptosis and decrease in cell proliferation ( Fig. 3b and Extended Data Fig. 8a-d ). To ask whether IAPP can also inhibit glycolysis in human cancer cell lines, we transfected H1299 cells with siDNp63, siDNp73 or IAPP ( Fig. 3a ). Knockdown of DNp63 or DNp73 or expression of IAPP resulted in an inhibition of glycolysis ( Fig. 3c, d ) and glucose uptake (Extended Data Fig. 8e , g), accumulation of ROS ( Fig. 3d-f ), and induction of apoptosis ( Fig. 3d , g, h). We inhibited ROS in these cells using N-acetyl-L-cysteine (NAC) and observed no apoptosis ( Fig. 3d-h) . Previous studies have indicated that IAPP inhibits glycolysis by increasing intracellular G-6-P in turn leading to an inhibition of hexokinase 21, 26 . We measured the levels of intracellular G-6-P in H1299 cells and found that cells expressing high levels of IAPP (H1299-siDNp63, H1299-siDNp73, or H12991IAPP) also had high levels of G-6-P while knockdown of IAPP resulted in a diminution in G-6-P (Extended Data Fig. 8f , g). Overexpression of glucose hexokinase II (HKII) led to a rescue of the glycolytic capacity of H1299 cells expressing siDNp63 or siDNp73 to levels similar to those in parental H1299 cells ( Fig. 3c-g) . These results indicate that IAPP inhibits glycolysis through the inhibition of HKII. We found that treatment of H1299 cells with pramlintide led to similar effects on glycolysis and apoptosis ( Fig. 3g-n) . Taken together, these o-u, Quantification of the indicated thymic lymphomas, n 5 5 mice per group. Significance indicated by the asterisks, P , 0.005. v, Quantification of in vivo pyruvate to lactate conversion using dynamic magnetic resonance spectroscopy as a measurement of glycolysis, n 5 3 mice, P , 0.005. w, Immunohistochemistry for reactive oxygen species (ROS) or cleaved caspase 3. Positive nuclei are brown.
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data demonstrate that IAPP and pramlintide inhibit glycolysis through the inhibition of HKII.
IAPP is a secreted protein and binds to the calcitonin receptor (CALCR) and RAMP3 (ref. 27 ). To determine whether IAPP functions through these receptors to inhibit glycolysis, secreted media from H1299 cells expressing siDNp63 (siDNp63 M ) or siDNp73 (siDNp73 M ), which contains secreted IAPP ( Fig. 4a and Extended Data Fig. 9a, b) , was added to H1299 cells resulting in inhibition of glycolysis ( Fig. 4b ) and induction of ROS and apoptosis ( Fig. 4c, d) . In contrast, when these media were used to treat H1299 cells with knockdown of CALCR or RAMP3, glycolysis was not inhibited and ROS and apoptosis were not induced ( Fig. 4b-d ), indicating that the CALCR and RAMP3 receptors are critical for IAPP function. We also treated the H1299 cells with media from H1299 cells expressing siDNp63 (siDNp63 M ) or siDNp73 (siDNp73 M ) and an amylin inhibitor, which led to high levels of glycolysis (Extended Data Fig. 9c ) and low levels of ROS and apoptosis ( Fig. 4c, d ). IAPP causes activation of the NLRP3 inflammasome 28 , which has been shown to be antitumorigenic in certain cancers via IL-18 processing 29 . We blocked caspase-1 using an inhibitor and found that it prevented apoptosis of H1299 cells (Fig. 4d ), demonstrating that pyroptosis may also be an important mechanism of action of IAPP.
To demonstrate the importance of the calcitonin receptor in vivo, we treated p53 2/2 mice with thymic lymphomas at 10 weeks of age with pramlintide and a calcitonin receptor inhibitor ( Fig. 4e -m) and found that this inhibition rendered pramlintide ineffective, demonstrating the importance of the calcitonin receptor for IAPP/amylin/pramlintide function ( Fig. 4n ). To further determine the anti-tumorigenic efficacy of 
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pramlintide in cells with p53 deletions or mutations, we treated additional human cancer cell lines 30 with pramlintide and a calcitonin receptor inhibitor, resulting in increased glycolysis, decreased ROS and apoptosis (Extended Data Fig. 9d -i). We assessed patient survival using data from the Cancer Genome Atlas (TCGA) of patients with p53 mutations and found that co-expression of IAPP, CALCR and RAMP3 correlated with better patient survival in basal breast cancer (Fig. 4o) , colorectal cancer and lung squamous cell carcinoma (Extended Data Fig. 9j, k) .
Reactivation of p53 activity in tumours results in tumour suppression 1,2 . We have focused on interactions between the three p53 family members and have revealed a novel strategy to target p53-deficient and mutant cancers through amylin-based therapies like pramlintide.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Generation of DNp73 conditional knockout mice. The Cre-loxP strategy was used to generate the DNp73 conditional knockout allele (DNp73fl). Genomic p73 DNA from intron 3 to intron 39 was amplified from BAC clone DNA (BAC RP23-186N8, Children's Hospital Oakland Research Institute). loxP sites flanking exon 39 of p73 and neomycin (neo) gene flanked by frt sites inserted in intron 39 were cloned into pL253 31 . Mouse embryonic stem cells (G4) electroporated with the targeting vector were analysed by Southern blot analysis for proper targeting of the DNp73 allele. Resulting chimaeras were mated with C57BL/6 albino females and genotyped as described below. Mice with germ line transmission of the targeted allele (conditional, flox neo allele, fn) were crossed to the FLPeR mice to delete the neo cassette. Resulting progeny were intercrossed with Zp3-cre (C57BL/6) 32 transgenic mice. DNp73 fl/1 ;Zp3-cre females were mated with C57BL/6 males to generate DNp73 1/2 mice. The DNp73 1/2 mice were intercrossed to generate DNp73 2/2 mice. Compound mutant mice were generated by intercrossing the DNp63 1/2 and The primers for DNp63WT, DNp63KO, DNp63flox and p53 were previously described 15, 16 . Cell lines. Mouse embryonic fibroblasts (MEFs) for the indicated genotypes were generated as described previously 9 . Human lung adenocarcinoma cells (H1299), colorectal adenocarcinoma cells (SW-480) and breast adenocarcinoma cells (MDA-MB-468) were purchased from ATCC and cutaneous SCC cell lines (SRB12, COLO16) 30 were a gift from K. Y. Tsai. The MEFs, SW-480 and MDA-MB-468 cells were cultured in DMEM (Cellgro) and H1299 cell lines were cultured in RPMI 1640 (Cellgro). The SRB12 and COLO16 cell lines were grown in DMEM/Ham's F12 50/50 (Cellgro). All cell lines used in the study tested negative for mycoplasma. Immunohistochemistry. Mice thymic lymphomas or thymi were dissected, fixed in 10% formalin, and embedded in paraffin. Sections were de-waxed in xylene and re-hydrated using decreasing concentrations of ethanol. Antigens were unmasked in citrate buffer unmasking solution (Vector Laboratory) followed by incubation with blocking solution, and 18 h incubation at 4 uC with the following antibodies: cleaved caspase 3 (1:200) (Cell Signaling), PCNA (1:500) (Cell Signaling), malondialdehyde (1:50) (Abcam). Visualization was performed using the ImmPact DAB peroxidase substrate kit (SK4105, Vector Laboratories) and counter-stained with haematoxylin (H-3401, Vector Laboratories). The slides were mounted using Vecta-Mount (H-5000, Vector Laboratories). Images were acquired using a Zeiss Axio microscope and analysed with ProgRes Capture Pro 4.5 software. Senescence-associated b-galactosidase staining. Senescence-associated b-galactosidase staining on mouse thymic lymphoma was performed as described previously 33 . Quantitative real time PCR. Total RNA was prepared from MEFs or mouse tissues using TRIzol reagent (Invitrogen) 4, 8, 34 . Complementary DNA was synthesized from 5 mg of total RNA using the SuperScript III First-Strand Synthesis Kit (Invitrogen) according to the manufacturer's protocol followed by qRT-PCR using the SYBR Fast qPCR master mix (Kapa Biosystems). qRT-PCR was performed using a ABI 7500 Fast Real-time PCR machine. Primers for mouse TAp63, DNp63, PUMA, Noxa, bax, PML, p16 and p21 (refs 4, 34) and human TAp63, DNp63 and GAPDH were used as described previously 4, 34 . Human primers for PUMA, Noxa, bax, PML, p16, p21 were used as described previously 33 and GLS2 and TIGAR as described Western blot analysis. Fifty micrograms of protein were electrophoresed on a 10% or 15% SDS PAGE and transferred to PVDF membrane as described previously 4, 8, 34 . Blots were probed with anti-p63 (1:500) (4A4, Santa Cruz), anti-TAp63 (1:1,000) (BioLegend), anti-TAp73 (1:500) (IMG-246, Imgenex), anti-p73 (mouse) (1:250) (IMG-259A, Imgenex), anti-p73 (1:1,000) (human) (EP436Y, Abcam), anti-p53 (WT) (1:1,000) (CM5, Vector Labs), anti-IAPP (1:1,000) (ab103580, Abcam), anti-His (1:1,000) (G18, Santa Cruz), anti-hexokinase II (1:10,000) (C64G5, Cell Signaling), anti-calcitonin receptor (1:1,000) (ab11042, Abcam), RAMP3(1:1,000) (H125, Santa Cruz), and cleaved caspase 3 (1:1,000) (Asp 175, Cell Signaling), at 4 uC for 18 h followed by incubation for 1 h at room temperature with the appropriate secondary antibodies conjugated to horseradish peroxidase (1:5,000) (Jackson Lab). b-Actin (Sigma 1:5,000) was used as a loading control. Detection was performed using the ECL Plus Kit (Amersham) following the manufacturer's protocol and X-ray autoradiography. Characterization of thymus using flow cytometry. Thymi from 4-week-old mice and thymic lymphomas from 10-week-old mice were collected 48 h after adenovirus infection. Single cells were obtained by homogenizing the thymi through a 0.75-mm filter. Cells were stained with CD3-PE (145-2C11), CD4-PerCP-Cy5.5 (RM4-5), CD8-APC (53-6.7), CD45-FITC (30-F11) (BDPharmingen), AnnexinV-Pacific Blue (A35122, Life Technologies), and 7-AAD (V35124, Invitrogen) and sorted using a BD Aria Cell Sorter or analysed using the LSR Fortessa Cell Analyzer and FlowJo software. Chromatin immunoprecipitation (ChIP). MEFs were grown to near confluence at passage 2 on DMEM media with 10% serum as previously described 9 . Thymocytes from 6-week-old mice were collected 48 h after adenovirus infection. Cellular proteins were cross-linked to DNA using 1% formaldehyde and chromatin was prepared as described previously 4, 8, 34 . TAp63 and DNp63 ChIP analysis was performed using a pan-p63 antibody (4A4, Santa Cruz) as described previously and the TAp73 ChIP was performed using a TAp73 antibody (ab14430, Abcam) and DNp73 ChIP was performed using a p73 antibody (IMG 259A, Imgenex). Putative TAp63 and TAp73 binding sites were scanned 3,000 bp upstream of the 59 UTR and in intron 2 of the IAPP gene. qRT-PCR was performed by using primers specific for the indi- Dual luciferase reporter assay. Luciferase assays were performed using p53 2/2 ; p63 2/2 and p53 2/2 ;p73 2/2 MEFs as described previously 35 . To generate the luciferase reporter gene (pGL3-IAPP), the DNA fragment containing the TAp63/TAp73binding site identified by ChIP was amplified from C57BL/6 genomic DNA by PCR with the following primers containing 59 XhoI and 39 HindIII cloning restriction enzyme sites: IAPP 59-ATACTCGAGGTGTTCAGGGAACCTTCGGT-39(forward) and 59-ATAAAGCTTCACCTGACCTCCAAACTCCC-39 (reverse). Similarly, a mutant version of the luciferase reporter gene (pGL3-IAPP Mut ) was generated using QuikChange Lightning (Agilent Technologies) following the manufacturer's instructions. The following primers 59-TATTGTTCTGACATCCAGCCTGATG TTGCCCAGTCTGGT-39(forward) and 59-ACCAGACTGGGCAACATCAGGC TGGATGTCAGAACAATA-39(reverse) were used to generate the mutant version. Reverse transfection. Cells were transfected with 50 nM siDNp63 (SASI_Hs02 00328367) (Mission siRNA, Sigma), siDNp73 (SASI_Hs02_00326884) (Mission siRNA, Sigma), siTAp63 (SASI_Hs01_00246771) (Mission siRNA, Sigma), siTAp73 (SASI_Hs02_00339573) (Mission siRNA, Sigma), siRAMP3 (SASI_Hs01_00199036) (Mission siRNA, Sigma), siCalcitonin receptor (SASI_Hs01_00077738) (Mission siRNA, Sigma), siIAPP (SASI_Hs01_00183962) (Mission siRNA, Sigma) or siNT (SIC_001) (Mission siRNA, Sigma) using Lipofectamine RNAiMAX (Invitrogen). The mixture of siRNA and Lipofectamine were combined together and added to the well followed by the addition of 200,000 cells per well in a six-well dish. Transfections and generation of IAPP-and hexokinase II-expressing cells. 3 3 10 5 cells were plated in 10-cm dishes. MEFs and human cancer cells were transfected with 8 mg Myc-DDK-IAPP (RC215074) (Origene) or 3.3 mg HKII (Plasmid 25529) (Addgene) using X-tremeGENE HP (Roche) and incubated for 48-60 h. Cells were selected with G418, MEFs (350 mg ml 21 ) and human cancer cells (500 mg ml 21 ) for a period of 9 days.
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Secreted IAPP protein concentration. Twelve hours after knockdown of DNp63/ DNp73 in human cancer cells, fresh serum-free media was added to the cells. Following a sixty-hour incubation, the media was collected and concentrated using Amicon Ultra-15 Centrifugal Filter Units (UFC901008, EMD Millipore). RNA sequencing and analysis. Five micrograms of polyA 1 RNA were used to construct RNA-Seq libraries using the standard Illumina protocol. Mouse mRNA sequencing yielded 30-40 million read pairs for each sample. The mouse mRNA-Seq reads were mapped using TopHat 36 onto the mouse genome and build UCSC mm9 (NCBI 37) and the RefSeq mouse genes. Gene expression and gene expression differences were computed using Cufflinks 36 . For each species, a combined profile of all samples was computed; mRNA abundance was mean-centred and Z-score transformed for each mRNA individually. Principal component analysis was executed using the implementation within the R statistical analysis system. Hierarchical clustering of samples was executed by first computing the symmetrical sample distance matrix using the Pearson correlation between mRNA profiles as a metric, supervised sample analysis was performed using the t-test statistics, and heat maps were generated using the heatmap.2 package in R. For gene signatures and pathway analysis gene list from the RNA-Seq comparing DN fl/fl ;p53 2/2 versus DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 were obtained at a P value , 0.01. The genes upregulated in the DNp63 D/D ;p53 2/2 and DNp73 D/D ;p53 2/2 and down regulated in the DN fl/fl ;p53 2/2 were selected. The relative fold change of the genes were calculated and sorted from highest to lowest. Genes with a greater than 1.5fold-increase were selected and run through the ingenuity pathway analysis (IPA) (Ingenuity Systems) to screen for pathways and processes. Genes from the selected pathways were cross-referenced with the Gene Set Enrichment (GSEA) (Broad Institute) data analysis, DAVID Bioinformatics Resource 6.7 and GSEA implementation at the Molecular Signature Database (MSigD) 37 . Magnetic resonance imaging. MRI imaging was performed at 10 weeks of age when the tumours were established and the volumes range from 2.3 mm 3 to 5 mm 3 . To reduce the variation between different groups of mice, a cohort of n 5 5 with similar tumour volumes was established and tumours regression was monitored by MRI. All mice were scanned once a week for a period of 35 weeks on a 7-T, 30-cm bore BioSpec MRI system (Bruker Biospin Corp., Billerica, MA) . Hyperpolarized magnetic resonance spectroscopy. Dynamic MR spectroscopy (MRS) of hyperpolarized (HP) [1-13 C] pyruvate was performed in vivo in tumourbearing mice. To achieve polarization, a 26-mg sample of pyruvic acid (Sigma-Aldrich, St. Louis, MO) with 15 mM of OX063 radical (GE Healthcare, Waukesha, WI) and 1.5 mM Prohance (Bracco Diagnostics Inc., Monroe Township, NJ) was polarized in a HyperSense DNP system (Oxford Instruments, Abington, Oxfordshire, UK) as previously described 38, 39 . The frozen sample was dissolved in a 4 ml buffer containing 40 mM Tris, 80 mM NaOH, and 50 mM NaCl, resulting in a final isotonic and neutral solution containing 80 mM [1-13 C]pyruvate. A dual-tuned 1 H/ 13 C linear radio frequency volume coil with 72 mm internal diameter (ID) was used in conjunction with imaging gradients with 12 cm ID. For anatomic imaging, the 1 H channel was used in transmit/receive mode. In addition to localizing scans, flow-weighted oblique gradient echo images (TE 5 1.4 ms; TR 5 55 ms; 90u excitation; 3 cm 3 3 cm field-of-view (FOV) encoded over a 64 3 64 image matrix) were acquired to confirm that the slice prescription for 13 C measurements would not be obfuscated by signals originating from within the heart. For carbon spectroscopy, the radio frequency volume coil was used in transmit-only mode in conjunction with a custombuilt 15-mm ID 13 C surface coil for signal reception. After dissolution, 200 ml of the HP [1-13 C]pyruvate solution was administered to the animals via tail-vein catheter. A slice-selective pulse-acquire sequence (TR 5 1,500 ms; 15u flip angle; 5 kHz spectral bandwidth; 2,048 spectral points; 8 mm oblique slab; 120 repetitions) was used for dynamic spectroscopy beginning approximately 15 s before injection. Data were processed to generate spectral time-courses of the HP-pyruvate and its lactate product. Spectra were phase adjusted and the area under the spectral peaks associated with [1-13 C]pyruvate and [1-13 C] lactate were integrated over time to reflect the overall signal observed from each metabolite over the course of the measurement. Total lactate signal, which could only arise from interaction of HP pyruvate with relevant metabolic enzymes, was normalized to the total signal from pyruvate. Glycolysis stress assay. Extra-cellular acidification rate (ECAR) was measured using the extracellular flux analyser (SeaHorse Bioscience XF96) following the manufacturer's instructions. Forty-eight hours after transfection, the cells were plated at a density of 1.5 3 10 4 cells per well in the XF 96-well cell culture plates. Twenty-four hours after seeding, the culture medium was replaced with 180 ml of running medium and incubated for 1 h at 37 uC in a non-CO 2 incubator. Before calibration, 20 ml of 50 mM glucose, 11 mM oligomycin and 650 mM 2DG were aliquoted into each port in the sensor cartridge. ECAR was measured after the addition of glucose and oligomycin and before the addition of 2DG. Extra-cellular acidification rate was normalized to mpH min 21 . Glucose uptake measurement. Glucose uptake was calculated as a measure of glucosedependent proton secretion from the maximum and basal glucose consumption after addition of 20 ml of 50 mM glucose and measured using the extracellular flux analyser (SeaHorse Biosciences XF96). Glucose-6-phosphate assay. Glucose-6-phosphate was measured using a glucose-6-phosphate assay kit (ab83426, Abcam) following the manufacturer's instructions. Forty-eight hours after transfection, 2 3 10 6 cells were collected, homogenized and passed through a 10-kDa spin-column filter. The eluate was collected and glucose-6-phosphate enzyme and substrate reaction was performed for 30 min and absorbance was measured at 450 nm. Proliferation assay. The transfected human cancer cells were plated at a density of 5 3 10 3 cells in 6 replicates in a 96-well dish. Twelve hours later, the cells were labelled with 10 mM EdU (59-ethynyl-29-deoxyuridine) for a period of 8 h. The assay was performed using the Click-iT EdU microplate assay (Invitrogen). Images were obtained using a Zeiss Axio fluorescent microscope and analysed using the AxioVision Image 4.5 software. Apoptosis assay. Cells were plated at a density of 1 3 10 4 cells in 6 replicates in a 96-well dish. Twelve hours later, the cells were washed with 13 annexin-binding buffer and a cocktail of 5 ml annexin V-Alexa Fluor 488 for 100 mg ml 21 propidium iodide (PI) and 2 mg ml 21 Hoechst 33342 (Invitrogen) was added. Images were captured using the Zeiss fluorescent microscope and Axiovision Image 4.5 software. Quantification of the percent apoptosis was obtained using a high-throughput immunofluorescence plate reader (Celigo). ROS assay. Cells were plated at a density of 1 3 10 4 cells in 6 replicates in 96-well dish. Twelve hours later, the cells were incubated with a cocktail of 5 mM concentration of CellROX Deep Red Reagent (C10422, Invitrogen) and 2 mg ml 21 Hoechst 33342 (Invitrogen) for 45 min at 37 uC. Images were captured using a Zeiss fluorescent microscope and Axiovision Image 4.5 software. Quantification of the percent ROS was obtained using a high-throughput immunofluorescence plate reader (Celigo) 40 .
In vitro adeno-Cre infection. DNp63 fl/fl ;p53 2/2 and DNp73 fl/fl p53 2/2 MEFs were plated at a density of 2.5 3 10 5 cells in 10-cm dishes before infection. Twelve hours later, MEFs were infected with Adeno-CMV-mCherry or Adeno-CMV-Cre-mCherry (Gene Transfer Vector Core Facility, University of Iowa). The cells were infected at a multiplicity of infection of 6,000 particles per cell. The efficiency of infection was quantified by assessing mCherry-positive cells. In vivo adeno-virus infection and IVIS Lumina imaging. All mice were anesthetized using isoflurane and 2% oxygen and placed on a custom bed. An incision was performed to expose the sternum. Using a 28.5G U100 Insulin syringe, Adeno-mCherry/ Adeno-Cre-mCherry (Gene Transfer Vector Core Facility, University of Iowa), Adeno-IAPP-mCherry(Vector Labs) or Adeno-shIAPP-U6-mCherry (TRCN0000416196, Mission shRNA) (Vector Labs) (sequence CCGGTGTAAATTCTCATGCTAAG AACTCGAGTTCTTAGCATGAGAATTTACATTTTTTG) was surgically administered by intra-thymic injection (5 3 10 12 viral particles per gram of body weight) through the 2nd and 3rd sternum. The incision was sealed using wound clips and mice were allowed to recover. To determine the efficiency of the in vivo viral delivery to the thymic lymphoma, IVIS Lumina Imaging (Perkin Elmer) was performed 48 h later. Images were captured using a Mid-600 series bandwidth filter and analysed using the Living Image data analysis software. shRNA knockdown. shRNA plasmids for Trp63 (Clone ID: V3LMM_508694) (sequence TGATCTTCAGCAACATCTC) and Trp73 (Clone ID: V3LMM_438557) (sequence TGCAGGTGGAAGACATCCA) were obtained from the MD Anderson shRNA core facility (Open Biosystems). 293T cells were plated at a density of 2.5 3 10 5 cells in 10 cm dishes. Three micrograms of shRNA and packaging vectors were transfected as described previously 4 . Cells were selected using puromycin (3 mg ml 21 ) for 7 days. In vitro and in vivo administration of 2-deoxy-D-glucose. 1 3 10 4 cells were plated in 6 replicate wells in a 96-well dish. Twelve hours later, the human cancer cells were treated with 50 mM final concentration of 2-deoxy-D-glucose (2DG) (D8375-5G, Sigma) for 1 h. Similarly, 2DG (500 mg per kg of tumour weight) (D8375-5G-Sigma) was administered directly into the lymphoma of mice as described earlier 39 . N-acetyl-L-cysteine treatment. 1 3 10 4 cells were plated in 6 replicate wells in a 96-well dish. Twelve hours later, cells were treated with N-acetyl-L-cysteine (NAC) (2 mM) (A8199, Sigma) final concentration for a period of 1 h. Amylin and caspase inhibitor treatment. 2 3 10 5 cells were plated in triplicate in a 6-well dish. Twelve hours later, cells were treated with Amylin peptide (5 mM) (A5972, Sigma) or with a caspase 1 inhibitor (20 mM) (Z-YVAD-FMK-218746, Calbiochem) for a period of 48 h. In vitro and in vivo administration of pramlintide acetate. 2 3 10 5 cells were plated in duplicate in a 6-well dish. Twelve hours later, cells were treated with 10 mg ml 21 pramlintide acetate (AMYLIN Pharmaceuticals) or placebo for a period of 48 h. pramlintide acetate (AMYLIN Pharmaceuticals) or placebo (sodium acetate/acetic acid) was surgically administered through non-invasive intra-thymic injection using a multiple dose protocol of pramlintide acetate (30 mg per gram of tumour weight). One injection per week for three weeks was administered directly into the thymic RESEARCH LETTER lymphoma of the animal. Another cohort of mice was treated bi-weekly for 3 weeks by intra-venous (IV) tail-vein injection of pramlintide acetate (45 mg per kg body weight) or placebo. The investigator was blinded to the treatment administered to each mouse. Tumour volumes were monitored weekly by MRI. Health and blood glucose levels of the treated animals were monitored weekly. In vitro and in vivo administration of calcitonin receptor antagonist. 2 3 10 5 cells were plated in duplicate in a 6-well dish. Twelve hours later, cells were treated with Calcitonin receptor antagonist (1 nM) (AC187, Tocris Bioscience) for a period of 48 h with or without simultaneous pramlintide treatment. Similarly, a chronic dose of calcitonin receptor antagonist (1 nmol per gram of tumour weight) was administered through non-invasive intra-thymic injections with one injection every week for a period of three weeks with or without simultaneous pramlintide treatment. Tumour volume was monitored and measured weekly by MRI. Survival analysis. Survival analysis was conducted for the IAPP, RAMP3 and CalCR gene in the following data sets: the Memorial Sloan Kettering Cancer Center and the TCGA Cancer cohort. We considered four major cancer types with high p53 mutation rates, which include lung squamous cell carcinoma 41 , head and neck squamous cell cancer 42, 43 , basal breast cancer 44, 45 , and colon cancer 46 . The co-expression of the three genes was analysed in cases only with p53 mutation. In all cases, we considered gene expression changes above or below two standard deviations with respect to the normal controls. The log-rank test and Cox P test was used to assess significance between the samples with or without expression changes of the IAPP, RAMP3 and CalCR gene using the cBioPortal for cancer genomics 47 . Statistics. Sample size for mouse cohorts in each experiment was chosen based on the penetrance of the thymic lymphoma phenotype of the p53 2/2 mouse model (80%). Twenty to thirty mice were used for survival analyses. Data were analysed using a one-way ANOVA test or a Student's t-test (two-sided) was used for comparison between two groups of data. A P value of 0.05 was considered significant. Data are represented as mean 6 s.e.m.
Extended Data Figure 1 | Generation and characterization of DNp73
conditional knockout mice. a, The DNp73 targeting vector was generated by inserting loxP sites (triangles) flanking exon 39 and a neomycin cassette (neo) flanked by frt sites (squares). The location of PCR primers in each allele is shown by blue arrows. The targeted region of the floxed allele is depicted by yellow-dashed lines. b, Southern blot analysis using the 59 probe shown in a and tail genomic DNA derived from mice of the indicated genotypes. c, PCR analysis using tail genomic DNA of the indicated genotypes. d, Western blot analysis using mouse embryo fibroblasts (MEFs) of the indicated genotypes. e, f, qRT-PCR in MEFs of the indicated genotypes, n 5 4, P , 0.005. Statistical significance is indicated by black asterisks.
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